Lu, Di
Wu, Xuanzhen
Wu, Wendy http://orcid.org/0000-0001-6048-405X
Wu, Shuangxiu
Li, Hui
Zhang, Yuhong http://orcid.org/0009-0002-6704-5919
Yan, Xuebin
Zhai, Jianxue
Dong, Xiaoying
Feng, Siyang
Zhang, Xueying
Sun, Fuming
Wang, Shaobo
Cai, Kaican http://orcid.org/0000-0003-4664-6694
Funding for this research was provided by:
Science and Technology Planning Project of Guangdong Province
Article History
Received: 24 April 2023
Revised: 5 November 2023
Accepted: 23 November 2023
First Online: 19 December 2023
Competing interests
: WW, SW, HL, YZ, XZ, FS, and SW are employees of Berry Oncology Corporation. Other authors had no declaration of conflicts of interest.
: The study was approved by the ethics committee of the Nanfang Hospital, Southern Medical University, Guangzhou, China (reference: NFEC-2019-014) and registered with ClinicalTrials.gov (reference: NCT03922230). Besides, this study was conducted with the approval of the Institutional Review Board of Nanfang Hospital of Southern Medical University, and written informed consent was obtained from all participants according to the institutional guidelines.